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Abstract Although studies of HLA and disease now date
back some 50 years, a principled understanding of that
relationship has been slow to emerge. Here, we examine
the associations of three HLA loci with medically refractory
pediatric acute lymphoblastic leukemia (pALL) patients in a
case–control study involving 2,438 cases and 41,750 con-
trols. An analysis of alleles from the class I loci, HLA-A and
HLA-B, and the class II locus DRB1 illuminates a spectrum
of extremely significant allelic associations conferring both
predisposition and protection. Genotypes constructed from
predisposing, protective, and neutral allelic categories point
to an additive mode of disease causation. For all three loci,
genotypes homozygous for predisposing alleles are at high-
est disease risk while the favorable effect of homozygous
protective genotypes is less striking. Analysis of A–B and
B–DRB1 haplotypes reveals locus-specific differences in
disease effects, while that all three loci influence pALL;
the influence of HLA-B is greater than that of HLA-A,
and the predisposing effect of DRB1 exceeds that of HLA-
B. We propose that the continuum in disease susceptibility
suggests a system in which many alleles take part in disease
predisposition based on differences in binding affinity to
one or a few peptides of exogenous origin. This work
provides evidence that an immune response mediated by
alleles from several HLA loci plays a critical role in the
pathogenesis of pALL, adding to the numerous studies
pointing to a role for an infectious origin in pALL.
Keywords HLA.Pediatric.Acutelymphoblastic
leukemia.Immunodominance.Allelicpolymorphism.
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Introduction
At least as far back as the discovery and original interpreta-
tion of the simple beta-hemoglobin variant responsible for
sickle cell disease (Allison 1954) the study of genetic vari-
ation and disease has been dominated by the concept that
there is a best version of the alleles present at a single locus.
“Wild type” is employed to refer to that optimal allele—self-
defined by its high frequency in the population—with all
other variation relegated to a “mutants” basket, or more
recently “minor allele” category. While neutral variants
and transitional and balanced polymorphisms are now rec-
ognized as contributors to empirically recorded genetic var-
iation, the dichotomy of good genes and bad genes remains.
The HLA complex of the major histocompatibility com-
plex of vertebrates with its multiple linked and highly poly-
morphic loci may challenge that conception. Interestingly,
HLA studies (now followed through the tens of thousands of
publications on HLA and disease) have been dominated by
the recording—allele by allele—of individual single gene–
disease relationships. Yet a strength of the HLA complex for
genetic studies is that a great deal is now understood of
HLA function down to the level of individual alleles. Each
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DOI 10.1007/s00251-012-0605-5HLA allele can be characterized in terms of its peptide
binding capacity for initiating the immune response and in
the case of alleles of the HLA class I loci, its ligand status for
alleles of the unlinked natural killer cell immunoglobulin-like
receptor (KIR) system (Bashirova et al. 2011). Taking advan-
tage of this background context, we evaluate the relationship
of HLAvariation to disease susceptibility in the predominant
pediatric oncologic disease. Our particular emphasis is on the
population level consideration of the contributions of all HLA
alleles present.
The first disease shown to have an association with the
major histocompatibility complex (MHC or HLA in
humans) was in murine models with leukemia (Lilly et al.
1964). The first human disease found to be associated with
HLA was childhood acute lymphoblastic leukemia (ALL)
(Walford et al. 1970); HLA serogroups A2 and B12 were
also found in a cancer family syndrome (Lynch et al. 1975).
Further evidence for the association of HLA with leukemia
came from atypical HLA segregation patterns observed in
leukemic families which show: (1) an increase in HLA-
identical non-affected sibs, (2) HLA homozygosity, and
(3) maternal class II DRB1 identity of disease association
haplotypes (Ryder et al. 1979; Sendid et al. 1998; reviewed
in Taylor et al. 2009). The lack of a disease-specific segre-
gation in families, however, suggests that HLA is not di-
rectly responsible for leukogenesis but may play a role in
susceptibility to development of leukemia or may be a
marker in linkage disequilibrium with another disease gene.
Not all studies of leukemia and HLA demonstrate associa-
tions, however (Hosking et al. 2011).
The evolution of infectious agents and their human hosts
has been a dynamic process. The maintenance of the ex-
treme polymorphism of the HLA has played an important
role in increasing the opportunity of survival when combat-
ing an ever-changing variety of pathogenic organisms. HLA
may contribute to the risk of developing leukemia not only
by recognition and presentation of viral or other peptides to
cytotoxic T cell lymphocytes and NK cells but also by
escape from host immune surveillance mechanisms (e.g.,
HLA class I downregulation associated with breast and
ovarian cancer (Vitale et al. 2005, 1998)), and it may reflect
accumulation of abnormalities associated with disease pro-
gression. HLA genotypes may play a significant role in the
modification of environmental risk and thereby influence
the development of high risk pediatric ALL.
The most common form of cancer in children is acute
lymphocytic leukemia, which comprises over 70% of can-
cers in the pediatric population worldwide (Goldberg et al.
2003). Analysis of HLA in relatives or in unrelated stem cell
donor registries is often requested to determine if an appro-
priate immunogenic match exists for ALL patients who are
not responding well to therapy and thus at high risk. We
examined European American ALL patients ages 2–16 from
records of patients being evaluated for possible stem cell
transplantation, designated pediatric acute lymphoblastic
leukemia (pALL). It is estimated that the great majority of
these pALL patients have precursor B cell ALL, as precursor
T cell ALL is much more difficult to reach second remission
once relapsed, as required for transplantation. Infants
(<2 years) with ALL were not examined, although they are
the group with the highest risk of treatment failure because
they have distinctive types of precursor B cell and mixed
lineage phenotypes with a different, predominantly genotoxic
phenotype (Greaves 1996; Greaves and Wiemels 2003). Uti-
lizing data from medically refractory pALL patients and adult
controls matched for ethnicity, sex, and geographic origin
from the National Marrow Donor Program (NMDP), we
studied the influence of variation at the HLA class I loci
(HLA-A and HLA-B) and the HLA class II DRB1 locus on
susceptibility to this common malignancy of childhood.
By testing and comparing the pALL susceptibilities of
each allele at each of three HLA loci in the population as a
whole, we uncover a near continuous array of protective and
predisposing allelic effects influencing disease outcome at
each locus. Based on studies of carefully examined diseases
with known immunogenic peptides differentially bound by
HLA molecules, our evidence suggests that development of
pALL is associated with a population level response of HLA
to infectious disease. The results of HLA association with
pALL fit well with a body of work suggesting an infectious
origin of this childhood cancer.
Results
Allele effects by locus
The influence of any HLA allele on pALL may be protec-
tive, predisposing, or neutral (exerting no effect). The im-
pact of HLA on medically refractory pALL is examined
here by analysis of individual allelic influences for each
class I HLA-A, HLA-B, and class II DRB1 loci, typed at
two-digit resolution in a Caucasian sample of 2,438 high-
risk pALL patients (4,876 chromosomes) and 41,750 con-
trols (83,500 chromosomes). The relationship of each allele
to pALL is expressed through an odds ratio (OR) calculated
in the context of all alleles at each locus. The impact of each
locus is revealed through the overall significance of the
deviation of the table consisting of the k alleles for a locus
by case and control frequencies. To help prevent the inclu-
sion of possibly spurious influences due to small sample
sizes, for inclusion as an individual category an allele must
have at least 50 observations in cases and controls com-
bined. The results of this test on each of the three loci are
shown in Table 1. For the HLA-A locus, the median sample
size of the 20 HLA-A alleles is 2,317. The overall log
410 Immunogenetics (2012) 64:409–419likelihood ratio or G test value is 145.3 which, with 19
degrees of freedom, results in a p value of 1.8E-21. Three
rare alleles of HLA-A (A*36, A*43, and A*80) were ex-
cluded. For HLA-B, the single allele test had 27 non-rare
alleles, a median size of 1,749, and a p value of 1.4E-55,
with nine HLA-B alleles too rare for individual inclusion.
For the class II DRB1 locus, all 12 alleles qualified for
testing with a median category size of 9,899 and a p value
of 1.8E-28. Each of the tests indicates extremely significant
differences in the distribution of patient and control allele
frequencies.
Association analysis of HLA-A reveals the 20 sampled
alleles ranging from odds ratios of 0.761 to 3,252 (Fig. 1a).
Based on an individual significance criterion of p<0.01,
four HLA-A alleles (A*33, A*01, A*03, and A*26) are
significantly protective, and six alleles predispose to high-
risk pALL (A*24, A*31, A*23, A*30, A*68, and A*74).
Overall, the 20 alleles at HLA-A indicate a continuum of
relationships, with the sense that larger sample sizes might
clarify the predisposing or protective status of several alleles
whose confidence intervals are close to, or include, an odds
ratio of 1.0. For the HLA-A locus, 50% of alleles as a whole
are either significantly predisposing or protective.
HLA-B with its intrinsically greater allelic polymorphism
has a total of six alleles significantly protective (B*14,
B*38, B*08, B*07, B*57, and B*44) and eight predisposing
to pALL (B*15, B*18, B*40, B*51, B*53, B*39, B*48, and
the assembled rare allele category “B*rare”). In the diagram
of HLA-B alleles sorted by odds ratios (Fig. 1b), we again
see a continuum of relationships to high-risk pALL
susceptibility with odds ratios ranging from 0.571 to
3.197, and 76% of alleles significantly deviant from OR0
1. As was true for HLA-A, it appears that, taken as a whole,
predisposing HLA-B alleles outnumber those conferring
protection. For the HLA-B locus 24.0% of alleles are neutral
with respect to disease.
Analysis of the HLA class II DRB1 locus reveals 12
alleles (Fig. 1c) in a similar continuous range, except
that the predisposing alleles DRB1*14, DRB1*10, and
DRB1*08 depart more dramatically from the continuous
changeinsusceptibilityseenintheothernineDRB1alleles.In
addition, the common and heterogeneous allele DRB1*04 is
also slightly predisposing (OR01.089). For HLA class II
DRB1, six of the 12 alleles are involved in disease protection
or predisposition with odds ratios ranging from 0.771 to
1.841.
Identified effects from each allele must be provisionally
regarded as marker effects, rather than directly contributing
to the disease. The two-digit HLA typing resolution avail-
able in this study hides considerable and often demon-
strably consequential additional genetic variability. We
examine subtypes of the protective alleles HLA-B*44,
known to be composed of many distinct alleles when
examined at higher resolution. Two of these are espe-
cially common in European Americans (B*44:02 at 9%
and B*44:03 at 5% frequency (Maiers et al. 2007)).
Examining a large sample of high-resolution-typed three
locus haplotypes (Maiers et al. 2007) shows that the
two common haplotypes A*29~B*44~DRB1*07 and
A*02~B*44~DRB1*04 effectively refer to the high-
Table 1 Pediatric ALL cases versus controls: summary of overall significance testing
Genetic factor pALL cases Controls Median no.,
samples per
category
k G P value Total no. favorable,
predisposing,
and neutral groups
Alleles 2n 2n
HLA-A 4,876 83,500 2,317 20 145.3 1.8E-21
HLA-B 4,876 83,500 1,749 27 335.7 1.4E-55
DRB1 4,876 83,500 9,899 12 159.4 1.8E-28
Genotypes Number Number
HLA-A/HLA-A 2,363 40,710 193 95 221.6 2.2E-29 6
HLA-B/HLA-B 2,169 38,410 147 162 403.2 9.3E-23 6
DRB1/DRB1 2,404 41,485 369 65 192.7 8.0E-15 6
Haplotypes 2n 2n
HLA-A~HLA-B 4,876 83,500 183 200 798.2 1.1E-72 8
HLA-B~DRB1 4,876 83,500 404 180 1096.1 1.6E-131 8
Rare category alleles (i.e., <50 observations) include HLA-A *36, *43, *80; HLA-B *46, *54, *59, *67, *73, *78, *81, *82, *83; DRB1 none. k is
the number of rows (genetic category) in 2×k test of heterogeneity using the log likelihood or G statistic. The degrees of freedom for this test are
(k−1). Genotype and haplotype categories assembled from significance of HLA-A, HLA-B, and DRB1 allelic testing are categorized as favorable–
protective (f), predisposing (p), or neutral (x)
Immunogenetics (2012) 64:409–419 411resolution versions of the two most common HLA-B*44 hap-
lotypes;A*29:02~B*44:03~DRB1*07:01hasapopulationfre-
quency of 0.019, while A*02:01~B*44:02~DRB1*04:01 has a
frequency of 0.026. The suggestion that the HLA-B*44:02
haplotype may be the primary source of the protective HLA-
B*44 signal may be tested by comparing the odds ratios of the
HLA-B*44:02 and HLA-B*44:03 alleles identified through
their three-locus haplotype proxies. The overall three locus
haplotype pALL risk of A*29~B*44~DRB1*07 is non-
significant at OR01.05 (confidence interval (CI)00.84,
Fig. 1 A continuum of pALL risk by HLA alleles at HLA-A, HLA-B,
and DRB1. Extreme statistical deviation between cases and controls is
present at each of the three loci (see Table 1 and Tables S2–S4) with at
least half of the alleles at each locus are either significantly protective
(blue) or significantly predisposing (orange). Odds ratio values are
listed at the top of each allele, with the vertical scale plotted in ln
(Odds) to allow positive and negative odds representation on the same
scale
412 Immunogenetics (2012) 64:409–4191.32). In contrast, the A*02~B*44~DRB1*04 haplotype
is significantly protective at OR00.67 (CI00.54, 0.83),
with the confidence intervals of the two haplotypes non-
overlapping. The protective effect of the HLA-B*44:02
allele can be interpreted as due to its carriage of a
protective influence above and beyond the HLA-B*44
defined marker alone.
Genotype effects
From the view of trait inheritance, an allele can act on its
own and in combination with its allelic homologue. For
HLA, these possible effects can also be extended to consid-
eration of alleles at other loci in the same gene family, for
example, the class I loci HLA-A and HLA-B. Allelic influ-
ence can also be a continuum of effect magnitudes from
protective to neutral to predisposing. To better understand
the influence of HLA on high-risk pALL, we start by
analyzing these possible higher order interactions by focus-
ing on the nominally significant predisposing and protective
alleles identified from the single locus analyses of HLA-A,
HLA-B, and DRB1.
Using the identified single allele influences [favorable–
protective (f), neutral (x) and predisposing (p)] on pALL, we
divide the possible HLA-A influence into a number of
qualitative categories. For a genotype of HLA-A, HLA-B,
or DRB1, an allele may act alone in the neutral heterozy-
gotes (px or fx), as homozygotes (ff, pp, or xx), or as mixed
heterozygotes (fp). For the haplotypes HLA-A−HLA-B and
HLA-B−DRB1, similar categories can be defined, with the
expansion of the two single allele effect heterozygotes to
one for each of the loci making a total of eight possible
categories. We thus tally case and control numbers for six
genotypic and eight haplotypic categories and calculate the
odds ratios for HLA association with pALL. The compari-
son of genotypic and haplotypic categories permit testing of
interaction effects within and between loci, locus-specific
differences in protection and causation and the nature of
interaction when protective and predisposing alleles occur
together, i.e., the mode of inheritance and interlocus effects.
Even with the 50-sample minimum size restriction on
testable genetic entities, 65 to 162 distinct testable geno-
types per locus are available, while the median number of
samples per category drops from 369 to 147 (Table 1). The
overall genotype case–control G tests are again extremely
significant for all three loci.
Genotypic groups are defined from the individual allele
results for each locus (Fig. 1 and Supplemental Tables).
These are classified according to allelic composition (p,
predisposing allele: OR<1; f, favorable–protective allele:
OR>1; x, neutral allele: OR01). Beginning with a compar-
ison of the six HLA-A genotype categories (Fig. 2a), we see
that single allele effects of protective-neutral heterozygotes
(fx) (identified as alleles HLA-A*01 and HLA-A*03)) are
significantly protective (OR00.83), as are the protective
Fig. 2 Mode of inheritance of pALL risk in HLA revealed by HLA
genotypic groups defined by allelic predisposition. Genotypic groups
are defined from the individual allele results for each locus (Fig. 1 and
Tables S5–S7). Homozygous predisposing genotypes (pp) are at great-
er risk than heterozygous predisposing genotypes (px) at all three loci
(a–c). For DRB1 the pp genotype is especially predisposing. Homo-
zygous favorable–protective genotypes (ff) always confer greater pro-
tection at each locus than the heterozygous fx genotypes but never
significantly so. The mixed fp genotypes have OR00 for HLA0A and
HLA-B, but for DRB1 fp OR>1. The neutral homozygotes xx have
OR00 at all three loci. For the mixed genotypes (fp) odds01 for HLA
A and HLA B, while for DRB1 odds >1. Both predisposing and
protective inheritance appear to be intermediate with predisposition
stronger than protection. Odds ratio values are listed at the top, with the
vertical scale plotted in ln(Odds) to allow positive and negative odds
representation on the same scale. p predisposing allele, OR>1;
f protective–favorable allele, OR<1; x neutral allele, OR01; mixed
refers to genotypes bearing both a p and f allele
Immunogenetics (2012) 64:409–419 413homozygotes ff (OR00.70). Because the protective and pre-
disposing genotypes are made up of those significantly devi-
ant alleles the direction of the deviations are expected; the
oddsoftheprotectiveHLA-Ahomozygotesarelowerthanthe
protective neural genotypes, but not significantly so.
Summarizing the genotypic outcomes from all three loci
(Fig. 1a, b, c), we note that homozygous predisposing gen-
otypes (pp) are at greater risk than heterozygous predispos-
ing genotypes (px) at all three loci (Fig. 2a,b ,c ) ;a s
described in “Methods,” here we use a natural logarithm
(ln) of the odds to allow positive and negative odds repre-
sentation on the same scale. For DRB1 the pp genotype is
especially predisposing. Homozygous favorable–protective
genotypes (ff) always confer greater protection at each locus
than the heterozygous fx genotypes, but never significantly
so. The mixed fp genotypes have OR00 for HLA0A and
HLA-B, but for DRB1 fp OR >1. The neutral homozygotes
xx have OR00 at all three loci. For the mixed genotypes (fp)
odds01 for HLA A and HLA B, while for DRB1 odds >1.
Both predisposing and protective inheritance appear to be
intermediate with predisposition stronger than protection.
Haplotype effects
Haplotype groups are defined from the individual allele
results for each locus (see Fig. 1 and Supplemental Tables).
As seen in Fig. 3, the six predisposing allele-bearing haplo-
types pp, px, and xp of A~B and B~DR all have OR >1.
Examining the predisposing haplotypes more closely shows
that the two pp bearing haplotypes (Ap~Bp and Bp~DRp,
Fig. 3a, b) each have greater predisposition than the hetero-
zygous px and xp haplotypes. The two Bx haplotypes predis-
posingdue tolinkage (Ap~Bx and Bx~DRp)havecontrasting
levels of pALL predisposition (OR01.07 and 1.90, respec-
tively), with Bx~DRp possessing much higher predisposition
than Ap~Bx; this is in contrast to the two Bp predisposing
haplotypes (Ax~Bp and Bp~DRx) that are very similar in risk
(OR01.25 and 1.33).
Haplotypes bearing favorable–protective alleles reveal a
different pattern. Of the three A~B and B~DRB1 protective
haplotypes, only those bearing a protective B allele have an
OR significantly less than 1. In contrast, the neutral Bx
haplotypes (Af~Bx and Bx~DRf) are very similar in risk
and not different from OR01. The mixed haplotypes (i.e., fp
and pf of A~B and B~DRB1; Fig. 3a, b) are each very close
to OR01, suggesting that predisposing and protective
effects on the same haplotype cancel each other out. The
two neutral xx haplotypes are each slightly protective, im-
plying locus interactions not evident in the ORs of the single
alleles from which they are derived. While all three loci
appear to influence pALL, HLA-B influence is greater than
HLA-A in both protective and predisposing directions,
while at DRB1 the effect is strongly predisposing.
Taken as a whole, these results reveal several new char-
acteristics of the action of the three HLA loci in medically
refractory pALL. The influence of HLA-A alleles on pALL
causation is seen to be weakest from both the genotypic and
haplotypic evidence, although HLA-A predisposing geno-
types do have a greater effect than predisposing-neutral
Fig. 3 The pALL risks of two locus haplotype groups defined by
allelic predisposition reveal locus-specific influences. Haplotype
groups are defined from the individual allele results for each locus
(see Fig. 1 and Tables S8 and S9). The six predisposing-allele bearing
haplotypes pp, px, and xp of A~B and of B~DR all have OR>1.
Examining the predisposing haplotypes more closely shows that the
two pp bearing haplotypes (Ap~Bp and Bp~DRp (a, b)) each have
greater predisposition than the heterozygous px and xp haplotypes. The
two Bx haplotypes predisposing due to linkage (Ap~Bx and Bx~DRp)
have contrast levels of pALL predisposition at OR01.07 and 1.90,
respectively, with Bx~DRp possessing much higher predisposition
than Ap~Bx, while the two Bp-only haplotypes are very similar at
OR01.25 and 1.33. Haplotypes bearing favorable or protective alleles
reveal a different pattern. Of the three A–B and B–DRB1 protective
haplotypes bearing favorable–protective alleles (f), only those bearing
a protective HLA-B allele have OR significantly <1, with the Af~Bx
and Bx~DRf haplotype risks not different from OR01. The mixed
haplotypes (i.e., fp and pf of A–B and B–DRB1 (a, b)) are each very
close to OR01, suggesting that predisposing and protective effects on
the same haplotype cancel each other out. The two xx haplotypes are
each protective, implying locus interactions not evident in the ORs of
the single alleles from which they are derived. While all three loci
appear to influence pALL, HLA-B influence is greater than HLA-A
while DR predisposition is greater than HLA-B predisposition. Odds
ratio values are listed at the top, with the vertical scale plotted in ln
(Odds) to allow positive and negative odds representation on the same
scale. p predisposing allele, OR>1; f protective–favorable allele, OR<
1; x neutral allele, OR01; mixed refers to Bp~DRf and Bf~DRp
haplotypes combined
414 Immunogenetics (2012) 64:409–419genotypes, suggesting a possible true HLA-A locus signal in
this instance. The HLA-A influence on pALL protection
was relatively weak and disappeared entirely in the HLA-
A–allele alone comparisons for HLA-A~HLA-B haplotype
predisposition. HLA-B alleles demonstrated both substantial
protective and predisposing effects with a consistent in-
crease in effect due to homozygosity of protective and
predisposing alleles. Viewed against the background of
B~DRB1 haplotypes, HLA-B alleles maintained evidence
of both protection and predisposition. For DRB1 genotypes
both protection and predisposition was present, but only the
doubly predisposing genotypes were of greater influence
than those having a single predisposing allele. From the
B~DRB1 haplotypes, DRB1 protection appears weak, but
the predisposing DRB1 alone and B~DRB1 genotype
effects were very strong and did not differ. This suggests
the possibility that the class II signal may be primarily or
even exclusively predisposing to disease.
Discussion
We have examined a large sample of medically refractory
pediatric ALL patients and compared them to a set of
carefully constructed controls at two HLA class I loci
(HLA-A and HLA-B) and one HLA class II locus
(DRB1). For each locus, the alleles present in the population
show a continuous range of associations with high-risk
pALL, from strongly predisposing to strongly protective
(Fig. 1). Many of the alleles at each locus were found to
be individually deviant from a neutral effect. Knowledge of
differential binding and presentation of peptide antigens to
the immune system to trigger T cell-mediated immune
responses helps clarify a population level understanding of
HLA alleles in disease predisposition. A single pathogen-
derived peptide associates with the HLA alleles at a locus
across a spectrum of binding affinities for the exposed
individuals in a population. This results in variation in
disease outcomes, depending in part on the HLA/peptide
characteristics accruing from each individual’sH L A
composition.
An immune response characterized by domination of just
one or two peptides of the many hundreds present in an
invading pathogen—termed immunodominance—is the
most common pattern encountered for both CD8+ (HLA
class I) and CD4+ (HLA class II) immuno-responses
(Richeldi et al. 1997; Yewdell and Bennink 1999). We infer
that the pattern of population-wide allelic association repre-
sented here may well reflect the effects of immunodomi-
nance; if the effectiveness of several HLA alleles differed
for a number of similarly reactive peptides, then a clearly
recognizable range of associations would not be evident.
While several steps in normal antigen presentation, ranging
from antigen processing to the survival of peptide MHC
attachment on a lymphocyte on the way from the periphery
to a lymph node can influence immunodominance, the key
factor is the kinetics and stability of the peptide/MHC bond
itself (Lazarski et al. 2005; Rosenman et al. 2011; Van Dyke
et al. 2011; Weaver and Sant 2009).
The spectrum of binding affinities for HLA-A and HLA-
B in relation to viral proteins in the context of host–patho-
gen co-evolution shows a general tendency for high binding
efficiencies to be associated with conserved proteins (Hertz
et al. 2011). This work also illustrated that HLA alleles
susceptible to dengue virus also had the lowest binding
affinities, and similarly, rapid progression of HIV-1 was
associated with HLA alleles having low binding affinity to
the gag protein. Another pertinent aspect of this work is that
HLA-A and HLA-B loci were shown to be capable of
distinct peptide binding relationships to a given virus. This
suggestion of an evolutionary division of labor between the
two loci isechoed in the finding here of differential influences
of HLA-A and HLA-B, as well as DRB1 (Figs. 2 and 3).
Studies on influenza virus immunity have been valuable
in elucidating the MHC/peptide relationship and provide
insights on the intricacies of immunodominance. Across
the five protein sequences of influenza virus, immunodomi-
nance due to peptides derived from two proteins was ob-
served to occur in two distinct class II MHC molecules
(Nayak et al. 2010; Snyder et al. 2008). Even with modest
overlap in CD4+-specific reactivity between the two MHC
molecules, a pattern of high to low binding affinities across
a population’s allelic repertoire could produce two (or more)
highly protective alleles with graded degrees of protection
as seen in our present study.
A case study of class II HLA variation and a simplified
immunogenic stimulus resulting in disease can be found in
chronic beryllium disease, a T cell-mediated lung condition
caused by hypersensitivity to beryllium due to genetic var-
iation at HLA class II DPB1 after beryllium exposure. Only
those individuals bearing glutamic acid at DPB1 position 69
of the antigen binding pocket P4 are susceptible (Richeldi et
al. 1997). But, reflecting the subtleties typically present in
HLA diseases, this relationship is influenced by additional
DRB1 and DPB1 genetic differences and environmental
variation (Rosenman et al. 2011; Van Dyke et al. 2011).
The P4 antigen-binding pocket of the DP molecule with
those DPB1 alleles having highest negative regional surface
charge creates highest susceptibility to chronic beryllium
disease followed by alleles with a relatively lower charge
valence, while a set of alleles with the lowest valence
contribute negligibly to susceptibility (Snyder et al. 2008).
Thus, the binding strength of the beryllium atom in the P4
pocket varies as a function of the local charge of the DP
molecule. Environmental factors (duration of beryllium ex-
posure and smoking) have the effect of smoothing the
Immunogenetics (2012) 64:409–419 415differences in susceptibility among DPB1 genotypes. Thus,
this example demonstrates the action of a single antigenic
factor leading to a range of HLA predispositions underlain
by differential antigen binding among HLA alleles.
A study directly pertinent to HLA–pathogen has been
clearly shown in research on the Borrelia burgdorferi
immunodominant OSPA peptide to DRB1 alleles in a sam-
ple of individuals divided into patients responsive and re-
fractory to antibiotic treatment of Lyme arthritis (Steere et
al. 2006). Ordering patients by the experimentally deter-
mined OSPA binding strength of the most common 14
DRB1 alleles in the European American population under
study revealed a continuous range of outcomes with the
binary responses to antibiotic treatment (responsive or re-
fractory) correlated with the binding affinity of the DRB1
alleles they carried. More complex patterns of peptide bind-
ing and stimulation of T cells created by a plurality of
pathogenic peptides would tend to mask such relationships,
as different peptides will likely bind most efficiently to
different alleles.
If a range of binding affinities among HLA alleles to a
peptide, as discussed here, is the norm, then the demonstra-
tion of a spectrum of differences in a case–control study will
require sufficient sample sizes to detect not just one most
deviant allele positively associated with disease but the
documentation of a full range of associations, including
negative associations that are statistically more difficult to
detect. Thus, studies employing smaller sample sizes will
only be capable of the identification of just one or a few of
the most common and most strongly positively disease-
associated alleles, as is the case for the great proportion of
HLA–disease studies over the last decades.
Infectious etiology
Our work reveals the action of a strong immune response
mediating the outcome pathogenesis of high-risk pALL and
complements a number of studies carried out over the last
several decades on the role of infectious agents in pediatric
leukemias. The body of epidemiologic evidence indicates
that the two major subtypes of pALL (precursor B and T
cell) have different etiologies (Davies et al. 2004;E d e n
2010; Goldberg et al. 2003; Greaves 2006, 1997; Uckun et
al. 1998). These leukemias are likely a result of both envi-
ronmental and genetic factors, with the risk of developing
leukemia involving multiple genes conferring susceptibility
to the development of malignancy. There is now strong
evidence that immunologic mechanisms may be involved
in the etiology of malignancy in pediatric precursor B cell
ALL and therefore a comprehensive evaluation of the asso-
ciation of the HLA system with disease susceptibility is of
considerable interest. The HLA system interacts with infec-
tious and environmental agents and presents foreign
peptides to circulating cytotoxic T lymphocytes and natural
killer (NK) cells. It is the HLA+peptide+T cell receptor
restriction complex that acts to determine “self” and “non-
self” antigens, and modulates the resulting immune re-
sponse. HLA-influenced modulation of immune response
may play a critical role in the development of B cell pALL
through differential antigen presenting capabilities and en-
suing immunologic reactions.
Epidemiologic factors from lifestyle indicators (including
socioeconomic status, parental occupation, urban versus
rural status), disease clustering as in Kinlen’s “population
mixing” hypothesis (Kinlen 1988, 1997), and the timing of
exposure to infection, as in Greave’s “delayed-infection”
hypothesis (Greaves 1993, 1988, 1997) all support a role
for infection in the etiology of pALL. In common pediatric
ALL, a two-step susceptibility model is often used to de-
scribe its etiology, with the first step including an in utero
chromosomal rearrangement followed by a second postnatal
“hit.” In this hypothesis, genetic susceptibility, which by
itself is not uncommon, is neither sufficient nor necessary
but may contribute to the risk, acting as a promoter rather
than an initiator of neoplastic disease (Taylor et al. 2008;
Greaves 2006). Greaves and others also hypothesized that
early life exposure to infection is essential to organize the
adaptive immune complex into an efficient response system;
a delay in exposure to infection could thus result in prolif-
erative stress on pre-leukemic stem cells leading to further
mutations and malignancy (Greaves 2006, 1997; Greaves
and Alexander 1993;T a y l o r1994; Thorsby 1997). This
theory is in accord with the “hygiene hypothesis” and im-
munologic organization, whereby the lack of early infec-
tions results in a disorganized immunologic system with
resultant autoimmune disease. There is also a correlation
between childhood allergies, type I diabetes, and pALL
which may mean that they share common infectious risk
factors. A substantial body of epidemiologic data exists
supporting an infectious etiology of pALL (Greaves 2006;
Little 1999; McNally and Eden 2004; O'Connor and Boneva
2007). Moreover, recent evidence on exposure to common
childhood infections, as measured by day care attendance,
birth order, and common childhood infections in infancy
strongly supports a protective role for early infection in
common childhood ALL (Urayama et al. 2010).
Interpreting HLA genetics
We have shown that, even at the relatively stringent cutoff of
p<0.01, at least half of the alleles at each of HLA-A, HLA-
B, and DRB1 are significantly associated with either pre-
disposition to or protection from medically refractory
pALL. A pattern of a continuum of risk association to the
disease is present for alleles at each of the loci. Taken as a
whole, the distributions of frequencies of alleles at each
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different using formal statistical tests. Genotypic groupings—
categories of genotypes based on the identified deviant alleles
−demonstrate that homozygous effects (revealing additive or
intermediate modes of inheritance) are most striking in the
predisposing alleles of each locus. Attributions of interlocus
effects among loci are explored with disease risks of the two
locus haplotypes A~B and B~DRB1. The HLA-A allelic
contribution in the haplotype context is less than that of
HLA-B alleles for both protective and predisposing effects,
while at the same time predisposing alleles from both HLA-A
and HLA-B loci on the same haplotype have a significantly
greater effect than HLA-A or HLA-B alleles alone. For
B~DRB1 haplotypes, the B~DRB1 combination of two pro-
tective alleles is significantly more protective than that of a
haplotypehavingonlyoneHLA-BoroneDRB1predisposing
allele. This suggests that HLA-B and DRB1 alleles may
synergistically increase protection. For the predisposing
B~DRB1 haplotypes, DRB1 effects were shown to greatly
exceed those of HLA-B-only haplotypes. This evidence
points to a distinct action of the class II DRB1 locus variation
in disease susceptibility relative to that of class I loci.
Although the haplotype analysis here suggests contribution
from linked loci in the development of pALL, there are addi-
tional tightly linked polymorphic candidate HLA loci that may
be contributing to the observed effects. Notable HLA class I
and class II loci in high linkage disequilibrium and tight
linkage with two of the loci are examined here: HLA-C with
HLA-BandtheDQA1~DQB1lociwithDRB1.Variationatall
three of the HLA class I loci (HLA-A, HLA-C, and HLA-B)
play a role in determining the activity of the NK cell system of
KIR loci, and this is especially true of HLA-C. Some of the
HLA-A and HLA-B influences on pALL may be indirect
influences emanating from the unlinked KIR system acting
through the class I loci (Bashirova et al. 2011). Finally, we
mention the possibility of indirect influence, again through
linkage disequilibrium, of non-HLA immune function loci
within the HLA complex, including tumor necrosis factor
alpha (TNF-α).
In the current study, we have identified a continuum of
susceptibilities in alleles of three HLA loci with pALL. We
argue thatoneexplanation forthispattern isvariablepathogen
binding under a regimen of immunodominance. Various ave-
nues of future work can be suggested. It would be good to
confirm the basic HLA-A, HLA-B, and DRB1 results with
coincident studies on the other class II loci and HLA-C, as
well assimultaneousgenotypingofKIR. HLA-C and DQ loci
are in strong linkage disequilibrium with HLA-B and DRB1,
respectively, so a first order evaluation of the roles of these
loci should be possible. Stem cell registries, because of their
large sample sizes and quality controls, are a good source of
material for studies on additional transplantable diseases that
could readily take place under this framework. Also, in this
regard, the hypothesis of variable binding of a single epitope
of pathogenic origin could be examined with bioinformatics
tools comparing the range of allelic associations at a locus
with known binding characteristics of each allele. Finally,
efforts to uncover the responsible infectious agent(s) underly-
ing pALL must be renewed.
Methods
Case and control samples
The two major subtypes of pediatric ALL are defined by
different cell lineages. The precursor B cell lineage predom-
inates at >85% of pALL with a frequency peak between the
ages of 2 and 5. The much rarer precursor Tcell form is found
in ~10–15% of pALL and more frequently in older children of
non-European heritage (Uckun et al. 1998). Treatment regi-
mens for the characteristically more severe precursor T cell
pALL have improved over the years so that it is no longer an
adverse risk factor (Davies et al. 2004; Goldberg et al. 2003;
Uckun et al. 1998). While most of the pediatric ALL cases are
cured by chemotherapy, approximately 10–15% of the cases
are refractory to that treatment and are then often referred for
transplantation with hematopoietic stem cells. Within the group
of pALL patients that are medically refractory and considered
for stem cell transplantation, the precursor B cell versus pre-
cursor Tcell lineages mirror the frequency of these types in the
pALL population as a whole. It is often difficult to get T cell
lineage pALL patients into remission after relapse, as required
for transplantation, leaving the majority of the patients advanc-
i n gt os t e mc e l lt r a n s p l a n t a tion with pre-B cell leukemia.
Pediatric ALL cases in this study consist of all European
American patients for whom preliminary hematopoietic stem
cell transplantation donor searches of the National Marrow
DonorProgramregistrywasperformedwithALLstatedasthe
disease. In that most pediatric ALL is cured by chemotherapy,
the present analysis is skewed toward more severe disease
with the potential for hematopoietic stem cell transplantation.
Patientswerechosenwithintheagerangeof2–16yearswhich
would capture the most typical pALL cases. HLA data from
the donor controls and cases were performed using consistent
DNA methods between the years of 1997 and 2002. Table S1
defines the sample numbers, male/female frequencies, and
breakdown according to geographic region tested.
Controls include sample data from adult donors (18–
29 years) recruited by the NMDP who self-identified as Eu-
ropean American (Table S1). Improperly matched control
datasets in HLA disease association studies can create errone-
ous correlations that are simply artifacts of differential geog-
raphy, gender, age, birth date, and ancestry between cases and
controls. Geographical variation in HLA across the USA has
been well documented, so the geographical distribution of the
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patients. Similarly, while HLA and gender effects are very
minor, they are considerably magnified by the combination of
the preponderance of females in the donor pool and the
increase of males in the pALL patient cohort. Differences in
age and birth date exist because of differing patterns of immi-
gration and admixture within self-identified groups over time
as well as protective/predisposing HLA-related effects on
human survival. Finally, there can be an underlying popula-
tion substructure beneath the level of self-identified race. In
our initial analyses, we documented an excess of Jewish
ancestry in the European-American patient population that
was corrected by removing individuals with likely Jewish
ancestry from both the case and control sets.
Based on Ashkenazi haplotype frequencies from the
Hadassah registry (Klitz et al. 2010), the European-
American patient sample was calculated to be 10% Jewish,
compared to 5% Jewish for the control sample. Jewish
haplotypes were then sampled from the Ashkenazi frequen-
cies with replacement and randomly selected subjects with
the haplotype were removed from both the patient and
control samples until the estimated Ashkenazi admixture
was 0% in both patient and control samples. This brought
the patient sample from 2,868 to 2,438 individuals and the
control population from 433,838 to 395,838 individuals.
The USA is split into four geographical regions based on the
first digit of the zip code (0,1 0 e a s t ;2 ,3 ,70 south; 4, 5, 6 0
midwest; 8, 9 0 west). Controls were subtracted optimally until
the distribution of controls in each region matched the patient
distribution. For the final step, after the geographical matching
of controls, females were removed from the control sample until
the control gender ratio matched the patient gender ratio. For
gender, the ratio of males to females in the patient sample was
1.59. To control for age, the controls over age 30 were removed
from the sample, leaving only controls between age 18 and 29.
Of 393,838 European-American controls, 341,291 remained
after geographical matching, 144, 142 remained after gender
matching, and 41,750 after controlling for age (Table S1).
Statistics
The overall difference between an HLA genetic category
(alleles at a locus, genotypes, or two-locus haplotypes) was
assessed through the RXC test of independence with the log
likelihood or G statistic (Sokal and Rohlf 1995), in which C
(patients and controls) are one dimension of a tally of counts
having R rows of distinct genetic categories (alleles, geno-
types, or haplotypes). The test of significance has k-1
degrees of freedom. This procedure tests for differences
between the overall patient and control distributions of a
genetic category. If the distributions are different, then the
individual contributions to that difference can be surveyed.
Individual genetic category differences (say for an individual
allele) are displayed with the OR and its confidence interval.
ORs are converted to ln(OR)andthen plotted tomake positive
and negative association space linearly equivalent, but the
untransformedORs are alsogiven along the top ofthe figures.
Following determination of nominally significant predispos-
ingandprotectiveallelesatHLA-A,-B,andDRB1(withPset
at <0.01), genotype and haplotype group categories are con-
structedfromthesedeviantallelestoassessdifferencesamong
these affective groupings: Favorable–protective (f) predispos-
ing (p), and neutral (x) carrying chromosomes construct six
possible genotypes (fx, ff, px, pp, fp, and xx). Similarly, the
two locus haplotypes have a possible eight groups (fx, xf, ff,
px, xp, pp, mixed [fp or pf] and xx). The ORs of the tallied
groups are evaluated and compared.
Thevariationindiseasesusceptibilityatthesecondallelein
a genotype and at alleles at other loci on the same haplotype
eachmodifythe observeddiseaseassociatedeffectsinanother
respect as well. Even a true allelic effect will, on average, be
reduced by the larger HLA genetic context in which it occurs.
This diminished measurement effect means that the true im-
pact of alleles may be greater than that demonstrated.
One issue regarding attribution of the HLA disease effects
deserves mention. If just one or a few alleles are protective of
disease (e.g., the most common HLA-B alleles*07, *08, and
*44, as observed here), then this combined effect could create
the appearance of predisposing alleles at the other end of the
predispositional spectrum even though these apparently sus-
ceptible alleles may be neutral with respect to disease. In this
study, the extreme p values resulting from both the overall
locus-wide tests and the individual p values of the predispos-
ing alleles make such an explanation less likely.
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